Oscar Izeboud, PhD
CEO20+ years of experience in biotech, including 14 years in investment banking at Kempen & Co and NIBC, leading over 50 IPO’s and M&A transactions across Europe and the USA.
Oscar joined Scenic in 2020 as CEO and is also a Board Director.
Prof. Sebastian Nijman
Founder & CSO20+ year career in Genomics research at leading academic institutions, including Oxford University and M.I.T..
10+ years of experience in biotech, including previous roles as CEO (Scenic) and COO (Haplogen).
Prof. Stephen Friend
Scientific Advisory BoardStephen is a visionary leader in Genetics, Cancer, and Digital Health. He is recognized for cloning the first human cancer susceptibility gene and for proposing the utility of synthetic lethality for cancer therapy.
He co-founded and led Rosetta Impharmatics (acquired by Merck) to pioneer mRNA expression profiling for cancer. He was at Apple from 2014-2017 to work on digital health, he is now a co-founder and President of 4YouandMe, the Founder and Chairman of Sage Bionetworks, and is a Visiting Professor of Connected Medicine at the University of Oxford.
Prof. Chas Bountra
Scientific Advisory BoardChas is Pro-Vice Chancellor for Innovation and Professor of Translational Medicine at the University of Oxford.
He is Director of the Centre for Medicines Discovery in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology. Chas is an invited expert on several government and charitable research funding bodies, and an advisor for many academic, biotech and pharma drug discovery programmes.
Prof. Ton Schumacher
Scientific Advisory BoardTon is a world-leading expert in Immuno Oncology. He is a senior member at The Netherlands Cancer Institute and professor of Immunotechnology at Leiden University.
He is a founder of AIMM Therapeutics, T cell factory (acquired by Kite Pharma/Gilead), Neon Therapeutics (acquired by BioNTech), and Neogene. He is also a Third Rock Venture partner. His long list of awards include, The Amsterdam Inventor Award, Queen Wilhelmina Cancer Research Award, Meyenburg Cancer Research Award, William B. Coley Award and the Jeantet-Collen prize.
Philippe Dro
Chairman of the BoardPhilippe has fulfilled leading roles in multiple biotech and medtech companies, including Themis Bioscience (acquired by Merck), GlycoVaxyn (acquired by GSK), Endoart (acquired by Allergan) and Axovan (acquired by Actelion).
Philippe serves on the Board of Luciole.
Oscar Izeboud, PhD
CEO20+ years of experience in biotech, including 14 years in investment banking at Kempen & Co and NIBC, leading over 50 IPO’s and M&A transactions across Europe and the USA.
Oscar joined Scenic in 2020 as CEO and is also a Board Director.
Alexandra Glucksmann, PhD
Independent Non-executive DirectorAlexandra is the President & CEO of Cedilla Therapeutics. Prior to that, she fulfilled multiple leadership roles including, VP at Millenium Pharmaceuticals, SVP at Cerulean Pharma, and most recently founding COO at Editas Medicine.
She also serves on the board of RegenxBio.
Prof. Thijn Brummelkamp
Founder & Non-executive Director20+ year career in award-winning Genomics research. Group leader at The Netherlands Cancer Institute and former Fellow at the Whitehead Institute for Biomedical Research in Cambridge USA.
Co-founder of Haplogen, Haplogen Genomics and Scenic Biotech. Thijn is also a Scenic Board Director.
Roel Bulthuis
Non-executive DirectorRoel Bulthuis is a Managing Partner at INKEF Capital. Prior to joining INKEF he was SVP and Managing Director of M-Ventures, worked in business development at Merck Serono and in investment banking (Fortis Bank).
He serves on the boards of Comet Therapeutics, iOnctura, Onward, NMD Pharma, Salvia Bio, Electronicx, VarmX, Calypso and QurAlis.
Edward van Wezel
Non-executive DirectorEdward is Founder and Managing Partner at BioGeneration Ventures (BGV) and combines over 20 years of experience in venture capital, pharma licensing, drug development and translational research.
He was founding investor and board member of Acerta Pharma (acquired by Astra Zeneca for $7B) and currently serves on the boards of several BGV portfolio companies.
Uciane Scarlett, PhD
Board ObserverUciane is Principal at OSI. She was previously entrepreneur in residence and on the investment team at Atlas Venture where se sat on the boards of Quench Bio, Dyne Therapeutics, and Navitor.
She also operated within Korro Bio and AVROBIO (AVRO). She was previously Director of BD & Strategy at Compass Therapeutics (CMPX). Uciane is the interim Exec Chair at T-Cypher Bio, and represents OSI on the boards of PepGen, MiroBio and DJS.
Prof. Sebastian Nijman
Founder & Board Observer20+ year career in Genomics research at leading academic institutions, including Oxford University and M.I.T..
10+ years of experience in biotech, including previous roles as CEO (Scenic) and COO (Haplogen).
